

False-Positive/False-Negative Trade-Offs in Bayesian Model Comparison

David Draper

*Department of Applied Mathematics and Statistics
University of California, Santa Cruz*

draper@ams.ucsc.edu
www.ams.ucsc.edu/~draper

SBIES, SANTA CRUZ

27 Apr 2012

(See **Draper (2012: Bayesian model specification: heuristics and examples**. In *Bayesian Theory and Applications* (Damien P, Dellaportas P, Polson N, and Stephens D, editors), forthcoming) for an **example of calibration cross-validation (CCV, page 11) in action.**)

Summary

- (1) The **big remaining challenge** in the **Bayesian paradigm** is **optimal model specification**, where **model** = {**prior, sampling distribution/likelihood**} for **inference/prediction** and **model** = {**prior, sampling distribution/likelihood, action space, utility function**} for **decision-making**; in this talk **model** = {**prior, sampling distribution/likelihood**}.
- (2) In **practice** You'll **almost always** have **uncertainty** about **how to specify** one or more of {**prior, sampling distribution/likelihood**}; this means **You'll need tools** for **model comparison**:
is M_1 **better** than M_2 ?
- (3) **Model comparison** is really a **decision problem** in **disguise**, which **should** be **solved** by **formulating** a **utility function** **specific** to the **given situation** and **maximizing** **expected utility**, but **this** is **hard work**; there's a **strong desire** for **model-comparison tools** based on **generic utility functions**.
- (4) Two such tools are **Bayes factors** and **log scores**.

Summary (continued)

(5) All scientists — Bayesian or non-Bayesian — need to pay attention to **calibration** (how often they get the right answer); this is a basic scientific imperative, and calibration results are part of the definition of “optimal” in (1).

(6) It's often not OK to do model comparison on the same data set on which You'll derive your inferential/predictive answers, based on how the model comparison comes out — this can lead to poor calibration; a method called **calibration cross-validation (CCV)** solves this problem, and allows Bayesians to compare models in a well-calibrated way.

(7) One consequence of (3) is that all statisticians — Bayesian or non-Bayesian — need to make (or at least pay attention to) calibration calculations in which (a) You (temporarily) assume an underlying data-generating mechanism M_{DG} (truth) and (b) You keep track of how often Your method recovers known truth (e.g., how often does model-comparison method A correctly identify M_{DG} ?).

Summary (continued)

(8) When **comparing** M_1 and M_2 , let's **agree to say** that **{choosing M_2 when M_{DG} is a special case of M_1 }** is a **false-positive mistake**, and **{choosing M_1 when M_{DG} is a special case of M_2 }** is a **false-negative mistake**.

(9) In **evaluating** the **calibration performance** of **model-comparison methods**, **standard asymptotic calculations** are often **irrelevant**; it's usually **far more useful** to **make calculations** or **run simulations** over a **realistic range** of **finite sample sizes**, comparing **false-positive** and **false-negative error rates**.

(10) **Popular (Bayesian and non-Bayesian) model-comparison methods** include **{AIC, Bayes factors, BIC, DIC, log scores}**; it **turns out** that **none of these methods dominates the others simultaneously** on **false-positive** and **false-negative performance**.

(11) But **You can draw** the following **broad conclusions** in the **situation** where M_2 is **more complicated** than M_1 (e.g., **when the number of parameters in M_2 is greater**):

Summary (continued)

(a) {AIC, DIC, log scores} behave **similarly**;

(b) {Bayes factors, BIC} behave **similarly**;

(c) {AIC, DIC, log scores} behave **differently** from
{Bayes factors, BIC};

(d) {AIC, DIC, log scores} tend to make **more false-positive mistakes** than {Bayes factors, BIC} and {Bayes factors, BIC} tend to make **more false-negative mistakes** than {AIC, DIC, log scores}.

(12) To choose a model-comparison method well in **Your problem**,
You need to think about the **real-world consequences** of
false-positive and **false-negative mistakes**; in **other words**, choosing
a **model-comparison method** is itself a **decision problem!**

(13) One **popular setting** in which M_2 is **more complicated** than M_1
is **equivalent to sharp-null hypothesis-testing** — e.g., the **data** are
IID $N(0, \sigma^2)$ under M_1 (H_0) and **IID $N(\mu, \sigma^2)$** under M_2 (H_A) — but in
practice there are **actually very few real-world situations** in which
this comparison is relevant.

Summary (continued)

Often Your uncertainty about μ is **continuous**, in which case the **right comparison** is between M_1 : IID $N(\mu, \sigma^2)$, $\mu \in (-a, +b)$ versus M_1 : IID $N(\mu, \sigma^2)$, $\mu \notin (-a, +b)$; in **this setting comparisons** between **{AIC, DIC, log scores}** and **{Bayes factors, BIC}** have **very different results** from those when comparing M_1 : IID $N(0, \sigma^2)$ with M_1 : IID $N(\mu, \sigma^2)$.

Old theorem: M_1 : IID $N(0, \sigma^2)$ versus M_1 : IID $N(\mu, \sigma^2)$, sample size n , $LS = \text{log scores}$;

(a) $P_{RS}[BIC \text{ chooses } M_2 | M_{DG} = M_2(\mu)] \rightarrow 1$ as $n \rightarrow \infty$ for all $\mu \neq 0$;

(b) $P_{RS}(BIC \text{ chooses } M_1 | M_{DG} = M_1) \rightarrow 1$ as $n \rightarrow \infty$;

(c) $P_{RS}[LS \text{ chooses } M_2 | M_{DG} = M_2(\mu)] \rightarrow 1$ as $n \rightarrow \infty$ for all $\mu \neq 0$;

(d) $P_{RS}(LS \text{ chooses } M_1 | M_{DG} = M_1) \rightarrow \boxed{0}$ as $n \rightarrow \infty$.

In other words, **asymptotic consistency** of **BIC** both under M_1 and M_2 , and **asymptotic consistency** of **LS** under M_2 but **not under** M_1 , when **comparing** the **sharp-null** M_1 with the **composite** M_2 .

However,

Summary (continued)

New theorem (Draper, 2012): M_1 : IID $N(\mu, \sigma^2)$, $\mu \in (-a, +b)$ versus M_1 : IID $N(\mu, \sigma^2)$, $\mu \notin (-a, +b)$, **sample size** n , **LS = log scores**;

(a) $P_{RS}[BIC \text{ chooses } M_2 | M_{DG} = M_2(\mu)] \rightarrow 1$ as $n \rightarrow \infty$ **for all** $\mu \neq 0$;

(b) $P_{RS}(BIC \text{ chooses } M_1 | M_{DG} = M_1) \rightarrow 1$ as $n \rightarrow \infty$;

(c) $P_{RS}[LS \text{ chooses } M_2 | M_{DG} = M_2(\mu)] \rightarrow 1$ as $n \rightarrow \infty$ **for all** $\mu \neq 0$;

(d) $P_{RS}(LS \text{ chooses } M_1 | M_{DG} = M_1) \rightarrow \boxed{1}$ as $n \rightarrow \infty$;

In **other words**, **asymptotic consistency** of both **BIC** and **LS**, both **under** M_1 and M_2 , when **comparing** the — often **much more realistic** — **composite** M_1 with the **composite** M_2 .

Thus the **comparison** between **BIC** and **LS** is **not as cut-and-dried** as the **Bayes-factor people** would have you **believe**.

The Basic Ingredients of a Statistical Problem

The **basic ingredients** in a **problem** involving **statistical inference**, **prediction** and/or **decision-making** are as follows:

- θ , something **unknown** to **You** (Good, 1950: a **generic person** wishing to **reason sensibly** in the presence of **uncertainty**).

θ could be **almost anything**, but (for **concreteness**) **think** of a **vector** in \mathbb{R}^k for **integer** $1 < k < \infty$ (all **finite-dimensional unknowns** can be **expressed in this way**);

- D , an **information source** (**data set**) that You **judge** to be **relevant** to **decreasing Your uncertainty** about θ .

D could **again** be **almost anything**, but **think** of a **vector** in \mathbb{R}^n for **integer** $1 \leq n < \infty$ (all **data sets** can be **expressed in this way**);

- \mathcal{B} , a (**true/false**) **proposition** of the form $(B_1 \text{ and } B_2 \text{ and } \dots \text{ and } B_b) = (B_1 B_2 \dots B_b)$ for **integer** $1 \leq b < \infty$, where the B_i are **propositions**, all regarded by **You** as **true**, that **specify Your background information, assumptions and judgments** about the **context** of the **problem** and the **data-gathering process**.

The **presence** of D creates a **dichotomy**:

- **Your information** about θ **{internal, external}** to D .

Q: How should this **information** be **combined** for **optimal information-processing**, to **solve** the **inference, prediction** and/or **decision-making problem**?

A: **One** (not necessarily the **only**) **logically-internally-consistent approach** is **provided** by a **theorem** of **Richard Cox** (1946), who regarded **probability** as an **expression** of **Your rational expectations** (**de Finetti** (1937) has a **similar theorem**, regarding **probability** as a **quantification** of **Your betting odds**).

The **primitive operator** in **Cox's framework** is $P(A|B)$, where A and B are **propositions**, with the **truth status** of A **unknown** to **You** and B regarded by **You** as **true**; from this **You** can **easily get** to **CDFs** (for **real-valued** θ) of the **form** $F_\theta(q|D\mathcal{B}) = P(\theta \leq q|D\mathcal{B})$ and **densities** of the **form** $p_\theta(q|D\mathcal{B}) = \frac{\partial}{\partial q} F_\theta(q|D\mathcal{B})$, which I'll **abbreviate** $p(\theta|D\mathcal{B})$ in **what follows**.

Cox's Theorem

Cox's Theorem says (informally) that, to be **logically internally consistent** and **not lose any information** in **Your information-processing**, **You must be prepared to specify** the following **two ingredients** for **inference** and **prediction**:

- $p(\theta|\mathcal{B})$, usually called Your **prior distribution** for θ (given \mathcal{B} ; this is **better understood** as a **summary of all relevant information** about θ **external** to D , rather than by appeal to any **temporal (before-after) considerations**);
- $p(D|\theta\mathcal{B})$, often referred to as Your **sampling distribution** for D given θ (and \mathcal{B} ; this is **better understood** as Your **conditional predictive distribution** for D given θ , before D has been **observed**, rather than by appeal to **other data sets that might have been observed**);

and the following **additional two ingredients** for **decision-making**:

- the set \mathcal{A} of **feasible actions** among which **You're choosing**, and
- a **utility function** $U(a, \theta)$, taking values on \mathfrak{R} and **quantifying** Your **judgments** about the **costs** and **benefits (monetary or otherwise)** that

would **ensue** if You chose **action** a and the **unknown** actually took the value θ — **without loss of generality** You can take **large values** of $U(a, \theta)$ to be **better than small values**.

The **theorem** further **says** that, having **specified** these **four ingredients**, You must **combine them** in the **following ways** to solve **Your inference, prediction and/or decision-making problem**:

- The **distribution** $p(\theta|D \mathcal{B})$ quantifies **all relevant information** about θ , both **internal and external** to D , and **must be computed** via **Bayes's Theorem**:

$$p(\theta|D \mathcal{B}) = c p(\theta|\mathcal{B}) p(D|\theta \mathcal{B}), \quad \text{(inference)} \quad (1)$$

where $c > 0$ is a **normalizing constant** chosen so that the **left-hand side** of (1) **integrates** (or **sums**) over Θ (the **set of possible values** of θ) to **1**;

- Your **predictive distribution** $p(D^*|D \mathcal{B})$ for future data D^* given the **observed data set** D **must be expressible** as follows:

$$p(D^*|D \mathcal{B}) = \int_{\Theta} p(D^*|\theta D \mathcal{B}) p(\theta|D \mathcal{B}) d\theta;$$

The Specification Burden

often there's **no information** about D^* contained in D if θ is known, **in which case this expression simplifies** to

$$p(D^*|D\mathcal{B}) = \int_{\Theta} p(D^*|\theta\mathcal{B}) p(\theta|D\mathcal{B}) d\theta; \quad \text{(prediction)} \quad (2)$$

- The **optimal decision** is to **choose the action** a^* that **maximizes the expectation** of $U(a, \theta)$ over $p(\theta|D\mathcal{B})$:

$$a^* = \operatorname{argmax}_{a \in \mathcal{A}} E_{(\theta|D\mathcal{B})} U(a, \theta) = \operatorname{argmax}_{a \in \mathcal{A}} \int_{\Theta} U(a, \theta) p(\theta|D\mathcal{B}) d\theta. \quad (3)$$

In **view of Cox's Theorem**, the **problem** now **becomes**:

How can **You specify** the **four ingredients** $p(\theta|\mathcal{B})$, $p(D|\theta\mathcal{B})$, and $\{\mathcal{A}, U(a, \theta)\}$ **well** (in fact, **can this be done optimally**)?

Cox's Theorem and its **corollaries** provide **no constraints on the specification process**, apart from the **requirement** that **all probability distributions be proper** (integrate or sum to 1).

For the **rest** of this **talk** I'll **concentrate** on **inference** and **prediction**, which **require specifying** $\{p(\theta|\mathcal{B}), p(D|\theta\mathcal{B})\}$ — **call** such a **specification** a **model** M for **Your uncertainty** about θ .

The Calibration Principle

As a **profession**, we currently **don't have a theorem**, like **Cox's Theorem**, that **tells us how to specify Bayesian models optimally**; the **best we can do at present** is **appeal to a set of principles** that can **provide some guidance**.

Here's one that makes good sense to me:

Calibration Principle: In model specification, it's **helpful to pay attention to how often You get the right answer**, by creating **situations in which You know what the right answer is and seeing how often Your methods recover known truth**.

The **reasoning** behind the **Calibration Principle** is as follows:

(axiom) You want to **help positively advance the course of science**, and **repeatedly getting the wrong answer runs counter** to this desire.

(remark) There's **nothing** in the **Bayesian paradigm** to **prevent** You from making **one or both** of the following **mistakes** — (a) choosing $p(D|\theta \mathcal{B})$ **badly**; (b) inserting **{strong information about θ external to D }** into the **modeling process** that turns out **after the fact** to have

Calibration Via Bayesian Decision Theory

been (badly) **out of step with reality** — and **repeatedly** doing this **violates the axiom** above.

(remark) Paying **attention to calibration** is a **natural activity** from the **frequentist** point of view, but a **desire** to be **well-calibrated** can be **given** an **entirely Bayesian justification** via **decision theory**:

Taking a **broader perspective** over **Your career**, not just **within** any **single attempt** to solve an **inferential/predictive problem** in **collaboration** with **other investigators**, Your **desire to take part positively** in the **progress of science** can be **quantified** in a **utility function** that **incorporates** a **bonus** for being **well-calibrated**, and in this **context** (Draper, 2012) **calibration-monitoring** emerges as a **natural and inevitable Bayesian activity**.

This **seems** to be a **new idea**: **logical consistency** justifies **Bayesian uncertainty assessment** but **does not provide guidance on model specification**; if You **accept** the **Calibration Principle**, **some of this guidance is provided**, via **Bayesian decision theory**, through a **desire** on Your part to **pay attention to how often You get the right answer**, which is a **central scientific activity**.

The M^* Approach

Having **adopted** the **Calibration Principle**, it makes sense to talk about an **underlying data-generating model** M_{DG} , which is **unknown to You**.

From **now on** I'll **focus** on the **sampling distribution** $p(D|\theta \mathcal{B})$.

Q: How can You **specify** $p(D|\theta \mathcal{B})$ in a **well-calibrated way**?

How not to do this: People **used to “solve”** the **problem** of what to **do** about **model uncertainty** by **ignoring** it: it was **common**, at least **through** the **mid-1990s**, to

(a) **use** the **data** D to **conduct** a **search** among **possible models**, settling on a **single (apparently) “best” model** M^* **arising** from the **search**, and then

(b) draw **inferences** about θ **pretending** that $M^* = M_{DG}$.

This of course **can lead** to **quite bad calibration**, **almost always** in the **direction** of **pretending You know more than You actually do**, so that, e.g., Your **nominal 90% posterior predictive intervals** for data

values not used in the modeling process would typically include substantially fewer than 90% of the actual observations (this is an example of what I mean by comparing actual performance with known truth).

A: One approach to solving this problem is calibration cross-validation (CCV):

- The M^* approach is an example of what might be called 1CV (one-fold cross-validation): You use the entire data set D both to model and to see how good the model is (this is clearly inadequate).
- 2CV (two-fold cross-validation) is frequently used: You (a) partition the data into modeling (\mathbb{M}) and validation (\mathbb{V}) subsets, (b) use \mathbb{M} to explore a variety of models until You've found a "good" one M^* , and (c) see how well M^* validates in \mathbb{V} (a useful Bayesian way to do this is to use the data in \mathbb{M} to construct posterior predictive distributions for all of the data values in \mathbb{V} and see how the latter compare with the former).

Calibration Cross-Validation (CCV)

- 2CV** is a **lot better** than **1CV**, but **what** do You do (as **frequently** happens) if M^* **doesn't validate well** in \mathbb{V} ?
- **CCV (calibration cross-validation)**: going out **one more term** in the **Taylor series** (so to speak),
- (a) **partition** the data into **modeling** (\mathbb{M}), **validation** (\mathbb{V}) and **calibration** (\mathbb{C}) subsets,
 - (b) use \mathbb{M} to explore a **variety of models** until You've found **one or more plausible candidates** $\mathcal{M} = \{M_1, \dots, M_m\}$,
 - (c) see **how well** the models in \mathcal{M} **validate** in \mathbb{V} ,
 - (d) if **none of** them do, **iterate (b) and (c)** until You do get **good validation**, and
 - (e) **fit the best model** in \mathcal{M} (or, better, **use BMA**) on the **data** in $(\mathbb{M} \cup \mathbb{V})$, and report both (i) **inferential conclusions** based on **this fit** and (ii) the **quality of predictive calibration** of **Your model/ensemble** in \mathbb{C} .

The **goal** with this **method** is both

- (1) a **good answer**, to the **main scientific question**, that has **paid a reasonable price** for **model uncertainty** (the **inferential answer** is based only on $(\mathbb{M} \cup \mathbb{V})$, making Your **uncertainty bands wider**) and
- (2) an **indication** of how **well calibrated** {the **iterative fitting process** yielding the **answer** in (1)} is in \mathbb{C} (a **good proxy** for **future data**).

You can use **decision theory** (Draper, 2012) to decide **how much data** to put in each of \mathbb{M} , \mathbb{V} and \mathbb{C} : the **more important calibration** is to You, the **more data** You want to put in \mathbb{C} , but **only up to a point**, because getting a **good answer** to the **scientific question** is also **important** to You.

This is **related** to the **machine-learning** practice (e.g., **Hastie, Tibshirani, Friedman** [HTF] 2009) of **Train/Validation/Test** partitioning, with one **improvement** (**decision theory** provides an **optimal way** to choose the **data subset sizes**); I **don't agree** with HTF that this can **only be done with large data sets**: it's even **more important** to do it with **small and medium-size data sets** (You just need to work with **multiple** $(\mathbb{M}, \mathbb{V}, \mathbb{C})$ **partitions** and **average**).

Modeling Algorithm

CCV provides a way to **pay the right price** for **hunting around in the data** for **good models**, motivating the following **modeling algorithm**:

- (a) **Start** at a model M_0 (**how choose?**); set the **current model** $M_{\text{current}} \leftarrow M_0$ and the **current model ensemble** $\mathcal{M}_{\text{current}} \leftarrow \{M_0\}$.
- (b) If M_{current} is **good enough to stop** (**how decide?**), **return** $\mathcal{M}_{\text{current}}$; **else**
- (c) **Generate** a new candidate model M_{new} (**how choose?**) and set $\mathcal{M}_{\text{current}} \leftarrow \mathcal{M}_{\text{current}} \cup M_{\text{new}}$.
- (d) If M_{new} is **better** than M_{current} (**how decide?**), **set** $M_{\text{current}} \leftarrow M_{\text{new}}$.
- (e) **Go to (b)**.

For **human analysts** the **choice** in (a) is **not hard**, although it **might not be easy to automate** in **full generality**; for **humans** the **choice** in (c) demands **creativity**, and as a **profession**, at **present**, we have **no principled way** to **automate** it; **here** I want to **focus** on the **question** in (d):

\boxed{Q} : Is M_1 **better** than M_2 ?

The Modeling-As-Decision Principle

This question **sounds fundamental** but **is not**: better **for what purpose?** This **implies** (see, e.g., Bernardo and Smith, 1995; Draper, 1996; Key et al., 1999) a

Modeling-As-Decision Principle: Making clear the **purpose to which the modeling will be put** transforms **model specification** into a **decision problem**, which **should be solved** by **maximizing expected utility** with a **utility function tailored** to the **specific problem under study**.

Some **examples of this** may be **found** (e.g., Draper and Fouskakis, 2008: **variable selection** in **generalized linear models** under **cost constraints**), but this is **hard work**; there's a **powerful desire** for **generic model-comparison methods** whose **utility structure** may provide a **decent approximation** to **problem-specific utility elicitation**.

Two such **methods** are **Bayes factors** and **log scores**.

- **Bayes factors.** It looks **natural** to **compare models** on the basis of their **posterior probabilities**; from **Bayes's Theorem** in **odds form**,

$$\frac{p(M_2|D\mathcal{B})}{p(M_1|D\mathcal{B})} = \left[\frac{p(M_2|\mathcal{B})}{p(M_1|\mathcal{B})} \right] \cdot \left[\frac{p(D|M_2\mathcal{B})}{p(D|M_1\mathcal{B})} \right]; \quad (4)$$

the **first term** on the right is just the **prior odds** in favor of M_2 over M_1 , and the **second term** on the right is called the **Bayes factor**, so in words equation (4) says

$$\left(\begin{array}{c} \text{posterior} \\ \text{odds} \\ \text{for } M_2 \\ \text{over } M_1 \end{array} \right) = \left(\begin{array}{c} \text{prior odds} \\ \text{for } M_2 \\ \text{over } M_1 \end{array} \right) \cdot \left(\begin{array}{c} \text{Bayes factor} \\ \text{for } M_2 \\ \text{over } M_1 \end{array} \right). \quad (5)$$

(**Bayes factors** seem to have **first been considered** by **Turing and Good** (~ 1941), as part of the effort to **break the German Enigma codes**.)

Odds o are related to **probabilities** p via $o = \frac{p}{1-p}$ and $p = \frac{o}{1+o}$; these are **monotone increasing transformations**, so the **decision rules** {choose M_2 over M_1 if the **posterior odds** for M_2 are greater} and {choose M_2 over M_1 if $p(M_2|D\mathcal{B}) > p(M_1|D\mathcal{B})$ } are **equivalent**.

Decision-Theoretic Basis for Bayes Factors

This approach does have a **decision-theoretic basis**, but it's rather **odd**: if You pretend that the **only possible data-generating mechanisms** are $\mathcal{M} = \{M_1, \dots, M_m\}$ for finite m , and You pretend that one of the models in \mathcal{M} must be the **true data-generating mechanism** M_{DG} , and You pretend that the **utility function**

$$U(M, M_{DG}) = \begin{cases} 1 & \text{if } M = M_{DG} \\ 0 & \text{otherwise} \end{cases} \quad (6)$$

reflects Your **real-world values**, then it's **decision-theoretically optimal** to choose the model in \mathcal{M} with the **highest posterior probability** (i.e., that choice **maximizes expected utility**).

If it's **scientifically appropriate** to take the **prior model probabilities** $p(M_j|\mathcal{B})$ to be **equal**, this rule reduces to **choosing the model with the highest Bayes factor in favor of it**; this can be found by (a) **computing the Bayes factor** in favor of M_2 over M_1 ,

$$BF(M_2 \text{ over } M_1 | D \mathcal{B}) = \frac{p(D|M_2 \mathcal{B})}{p(D|M_1 \mathcal{B})}, \quad (7)$$

Parametric Model Comparison

favoring M_2 if $BF(M_2 \text{ over } M_1 | D \mathcal{B}) > 1$, i.e., if $p(D|M_2 \mathcal{B}) > p(D|M_1 \mathcal{B})$, and calling the **better model** M^* ; (b) **computing the Bayes factor** in favor of M^* over M_3 , calling the **better model** M^* ; and so on up through M_m .

Notice that there's **something else** a bit **funny** about this: $p(D|M_j \mathcal{B})$ is the **prior** (not posterior) **predictive distribution** for the data set D under model M_j , so the **Bayes factor rule** tells You to **choose the model that does the best job of predicting the data before any data arrives**.

Let's look at the **general problem** of **parametric model comparison**, in which model M_j has **its own parameter vector** γ_j (of length k_j), where $\gamma_j = (\theta, \eta_j)$, and is **specified** by

$$M_j: \left\{ \begin{array}{l} (\gamma_j | M_j \mathcal{B}) \sim p(\gamma_j | M_j \mathcal{B}) \\ (D | \gamma_j M_j \mathcal{B}) \sim p(D | \gamma_j M_j \mathcal{B}) \end{array} \right\}. \quad (8)$$

Here the quantity $p(D|M_j \mathcal{B})$ that **defines the Bayes factor** is

Integrated Likelihoods

$$p(D|M_j \mathcal{B}) = \int p(D|\gamma_j M_j \mathcal{B}) p(\gamma_j|M_j \mathcal{B}) d\gamma_j; \quad (9)$$

this is called an **integrated likelihood** (or **marginal likelihood**) because it tells You to take a **weighted average** of the **sampling distribution/likelihood** $p(D|\gamma_j M_j \mathcal{B})$, but **NB** **weighted by the prior** for γ_j in model M_j ; as noted above, this may seem **surprising**, but it's **correct**, and it can lead to **trouble**, as follows.

The first trouble is **technical**: the **integral** in (9) can be **difficult to compute**, and may not even be easy to **approximate**.

The second thing to **notice** is that (9) can be **rewritten** as

$$p(D|M_j \mathcal{B}) = E_{(\gamma_j|M_j \mathcal{B})} p(D|\gamma_j M_j \mathcal{B}). \quad (10)$$

In other words the **integrated likelihood** is the **expectation** of the **sampling distribution** over the **prior** for γ_j in model M_j (evaluated at the **observed data set** D).

Example: Integer-valued data set $D = (y_1 \dots y_n)$; $\bar{y} = \frac{1}{n} \sum_{i=1}^n y_i$

Instability of Bayes Factors

$M_1 = \mathbf{Geometric}(\theta_1)$ likelihood with a **Beta** (α_1, β_1) prior on θ_1 ;

$M_2 = \mathbf{Poisson}(\theta_2)$ likelihood with a **Gamma** (α_2, β_2) prior on θ_2 .

The **Bayes factor** in favor of M_1 over M_2 turns out to be

$$\frac{\Gamma(\alpha_1 + \beta_1) \Gamma(n + \alpha_1) \Gamma(n\bar{y} + \beta_1) \Gamma(\alpha_2) (n + \beta_2)^{n\bar{y} + \alpha_2} (\prod_{i=1}^n y_i!)}{\Gamma(\alpha_1) \Gamma(\beta_1) \Gamma(n + n\bar{y} + \alpha_1 + \beta_1) \Gamma(n\bar{y} + \alpha_2) \beta_2^{\alpha_2}}. \quad (11)$$

With **standard diffuse priors** — take $(\alpha_1, \beta_1) = (1, 1)$ and $(\alpha_2, \beta_2) = (\epsilon, \epsilon)$ for some $\epsilon > 0$ — the **Bayes factor** reduces to

$$\frac{\Gamma(n + 1) \Gamma(n\bar{y} + 1) \Gamma(\epsilon) (n + \epsilon)^{n\bar{y} + \epsilon} (\prod_{i=1}^n y_i!)}{\Gamma(n + n\bar{y} + 2) \Gamma(n\bar{y} + \epsilon) \epsilon^\epsilon}. \quad (12)$$

This goes to $+\infty$ as $\epsilon \downarrow 0$, i.e., You can make the evidence in **favor** of the **Geometric model** over the **Poisson** as **large** as You want, **no matter what the data says**, as a function of a quantity near 0 that **scientifically** You have **no basis** to specify.

If instead You **fix and bound** (α_2, β_2) away from 0 and let $(\alpha_1, \beta_1) \downarrow 0$, You can **completely reverse** this and make the evidence in **favor** of the **Poisson model** over the **Geometric** as **large** as You want (for **any** y).

Approximating Integrated Likelihoods

The **bottom line** is that, when **scientific context** suggests **diffuse priors** on the **parameter vectors** in the **models** being **compared**, the **integrated likelihood values** that are at the **heart** of **Bayes factors** can be **hideously sensitive** to **small arbitrary details** in how the **diffuseness** is **specified**.

This has been **well-known** for quite awhile now, and it's given rise to **an amazing amount of fumbling around**, as people who like **Bayes factors** have tried to find a way to **fix** the problem: at this point the **list of attempts** includes **{partial, intrinsic, fractional} Bayes factors, well-calibrated priors, conventional priors, intrinsic priors, expected posterior priors, ...** (e.g., Pericchi 2004), and all of them **exhibit** a level of **ad-hockery** that's **otherwise absent** from the **Bayesian paradigm**.

Approximating integrated likelihoods. The goal is

$$p(D|M_j \mathcal{B}) = \int p(D|\gamma_j M_j \mathcal{B}) p(\gamma_j|M_j \mathcal{B}) d\gamma_j; \quad (13)$$

maybe there's an **analytic approximation** to this that will suggest how to **avoid trouble**.

Laplace Approximation

Laplace (1785) already faced this problem **225 years ago**, and he offered a **solution** that's often useful, which people now call a **Laplace approximation** in his honor (it's an **example** of what's also known in the **applied mathematics literature** as a **saddle-point approximation**).

Noticing that the **integrand** $P^*(\gamma_j) \equiv p(D|\gamma_j M_j \mathcal{B}) p(\gamma_j|M_j \mathcal{B})$ in $p(D|M_j \mathcal{B})$ is an **un-normalized version** of the **posterior distribution** $p(\gamma_j|D M_j \mathcal{B})$, and appealing to a **Bayesian version** of the **Central Limit Theorem** — which says that **with a lot of data**, such a **posterior distribution** should be **close to Gaussian**, centered at the **posterior mode** $\hat{\gamma}_j$ — You can see that (with a **large sample size** n) $\log P^*(\gamma_j)$ should be **close to quadratic** around that mode; the **Laplace idea** is to take a **Taylor expansion** of $\log P^*(\gamma_j)$ around $\hat{\gamma}_j$ and **retain** only the terms out to **second order**; the result is

$$\begin{aligned} \log p(D|M_j \mathcal{B}) &= \log p(D|\hat{\gamma}_j M_j \mathcal{B}) + \log p(\hat{\gamma}_j|M_j \mathcal{B}) \\ &\quad + \frac{k_j}{2} \log 2\pi - \frac{1}{2} \log |\hat{I}_j| + O\left(\frac{1}{n}\right); \quad (14) \end{aligned}$$

here $\hat{\gamma}_j$ is the **maximum likelihood estimate** of the **parameter vector** γ_j under **model** M_j and \hat{I}_j is the **observed information matrix** under M_j .

Notice that the **prior** on γ_j in model M_j enters into this **approximation** through $\log p(\hat{\gamma}_j | M_j \mathcal{B})$, and this is a term that **won't go away with more data**: as n increases this term is $O(1)$.

Using a **less precise Taylor expansion**, Schwarz (1978) obtained a **different approximation** that's the **basis** of what has come to be **known** as the **Bayesian information criterion (BIC)**:

$$\log p(y | M_j \mathcal{B}) = \log p(y | \hat{\gamma}_j M_j \mathcal{B}) - \frac{k_j}{2} \log n + O(1). \quad (15)$$

People often work with a **multiple** of this for **model comparison**:

$$BIC(M_j | D \mathcal{B}) = -2 \log p(D | \hat{\gamma}_j M_j \mathcal{B}) + k_j \log n \quad (16)$$

(the -2 **multiplier** comes from **deviance** considerations); **multiplying** by -2 induces a **search** (with this approach) for **models** with **small BIC**.

This **model-comparison method** makes an **explicit trade-off** between **model complexity** (which **goes up** with k_j at a $\log n$ rate) — and model **lack of fit** (through the $-2 \log p(D | \hat{\gamma}_j M_j \mathcal{B})$ **term**).

BIC and the Unit-Information Prior

BIC is called an **information criterion** because it resembles **AIC** (Akaike, 1974). which was derived using **information-theoretic** reasoning:

$$AIC(M_j|D \mathcal{B}) = -2 \log p(D|\hat{\gamma}_j; M_j \mathcal{B}) + 2 k_j. \quad (17)$$

AIC penalizes **model complexity** at a **linear rate** in k_j and so can have **different behavior** than **BIC**, especially with moderate to large n (**BIC** tends to choose **simpler models**; more on this later).

It's possible to work out what **implied prior BIC is using**, from the point of view of the **Laplace approximation**; the result is

$$(\gamma_j|M_j \mathcal{B}) \sim N_{k_j}(\hat{\gamma}_j, n\hat{l}_j^{-1}). \quad (18)$$

In the **literature** this is called a **unit-information prior**, because in **large samples** it corresponds to the **prior being equivalent to 1 new observation** yielding the **same sufficient statistics** as the **observed data**.

This **prior** is **data-determined**, but this **effect** is **close to negligible** even with only **moderate** n .

Bayes Factors; Log Scores

The BIC **approximation** to Bayes factors has the **extremely desirable property** that it's **free of the hideous instability of integrated likelihoods** with respect to **tiny details**, in how **diffuse priors** are specified, that **do not arise directly from the science of the problem**; in my view, if You're going to use **Bayes factors** to **choose** among **models**, You're **well advised** to use a **method like BIC** that **protects You from Yourself** in **mis-specifying those tiny details**.

I said back on **page 20** that there are **two generic utility-based model-comparison methods**: **Bayes factors** and **log scores**.

- **Log scores** are based on the

Prediction Principle: **Good models** make **good predictions**, and **bad models** make **bad predictions**; that's one **scientifically important** way You know a **model** is **good** or **bad**.

This suggests developing a **generic utility structure** based on **predictive accuracy**: consider first a **setting** in which $D = y = (y_1 \dots y_n)$ for real-valued y_i and the **models** to be **compared** are (as before)

$$M_j: \left\{ \begin{array}{l} (\gamma_j | M_j \mathcal{B}) \sim p(\gamma_j | M_j \mathcal{B}) \\ (y | \gamma_j M_j \mathcal{B}) \sim p(y | \gamma_j M_j \mathcal{B}) \end{array} \right\}. \quad (19)$$

When **comparing** a **(future) data value** y^* with the **predictive distribution** $p(\cdot | y M_j \mathcal{B})$ for it under M_j , it's **been shown** that (under **reasonable optimality criteria**) all optimal **scores** measuring the **discrepancy** between y^* and $p(\cdot | y M_j \mathcal{B})$ are **linear functions** of $\log p(y^* | y M_j \mathcal{B})$ (the **log** of the **height** of the **predictive distribution** at the **observed value** y^*).

Using this **fact**, perhaps the most **natural-looking** form for a **composite measure** of **predictive accuracy** of M_j is a **cross-validated** version of the resulting **log score**,

$$LS_{CV}(M_j | y \mathcal{B}) = \frac{1}{n} \sum_{i=1}^n \log p(y_i | y_{-i} M_j \mathcal{B}), \quad (20)$$

in which y_{-i} is the y **vector** with observation i **omitted**.

Somewhat **surprisingly**, Draper and Krnjajić (2010) have shown that a **full-sample log score** that **omits** the **leave-one-out idea**,

Full-Sample Log Score

$$LS_{FS}(M_j|y \mathcal{B}) = \frac{1}{n} \sum_{i=1}^n \log p(y_i|y M_j \mathcal{B}), \quad (21)$$

made **operational** with the **rule** $\{\text{favor } M_2 \text{ over } M_1 \text{ if } LS_{FS}(M_2|y \mathcal{B}) > LS_{FS}(M_1|y \mathcal{B})\}$, can have **better small-sample model discrimination ability** than LS_{CV} (in addition to being **faster to approximate** in a **stable** way).

If, in the spirit of **calibration**, You're prepared to **think about** an **underlying data-generating model** M_{DG} , LS_{FS} also has a **nice interpretation** as an **approximation** to the **Kullback-Leibler divergence** between M_{DG} and $p(\cdot|y M_j \mathcal{B})$, in which M_{DG} is **approximated** by the **empirical CDF**:

$$\begin{aligned} KL[M_{DG}||p(\cdot|y M_j \mathcal{B})] &= E_{M_{DG}} \log M_{DG} - E_{M_{DG}} \log p(\cdot|y M_j \mathcal{B}) \\ &\doteq E_{M_{DG}} \log M_{DG} - LS_{FS}(M_j|y \mathcal{B}); \quad (22) \end{aligned}$$

the **first term** on the **right side** of (22) is **constant** in $p(\cdot|y M_j \mathcal{B})$, so **minimizing** $KL[M_{DG}||p(\cdot|y M_j \mathcal{B})]$ is **approximately the same** as **maximizing** LS_{FS} .

Bayes Factors/BIC Versus Log Scores

What follows is a **sketch of recent results** (Draper, 2011) based on **simulation experiments** with **realistic sample sizes**; in my view **standard asymptotic calculations** — **choosing between the models** in $\mathcal{M} = \{M_1, M_2\}$ as $n \rightarrow \infty$ with \mathcal{M} **remaining fixed** — are **essentially irrelevant** in **calibration studies**, for **two reasons**:

(1) With **increasing n** , You'll want \mathcal{M} to **grow** to **satisfy Your desire** to do a **better job** of **capturing real-world complexities**, and

(2) **Data** usually **accumulate over time**, and with **increasing n** it **becomes more likely** that the **real-world process** You're modeling is **not stationary**.

- **Versions of Bayes factors** that **behave sensibly** with **diffuse priors** on the **model parameters** (e.g., **intrinsic Bayes factors**: Berger and Pericchi, 1996, and **more recent cousins**) tend to have **model discrimination performance similar** to that of **BIC** in **calibration (repeated-sampling with known M_{DG}) environments**; I'll show **results for BIC** here.

Example: Consider **assessing the performance** of a **drug**, for **lowering**

Clinical Trial to Quantify Improvement

systolic blood pressure (SBP) in **hypertensive** patients, in a **phase-II clinical trial**, and suppose that a **Gaussian sampling distribution** for the **outcome variable** is **reasonable** (possibly after **transformation**).

Two **frequent designs** in **settings** of this type have as their goals **quantifying improvement** and **establishing bio-equivalence**.

- (**quantifying improvement**) Here You want to **estimate** the **mean decline** in **blood pressure** under this drug, and it would be **natural** to choose a **repeated-measures (pre-post) experiment**, in which **SBP values** are obtained for **each patient**, both **before** and **after** taking the drug for a **sufficiently long** period of time for its **effect** to become **apparent**.

Let θ stand for the **mean difference** ($SBP_{before} - SBP_{after}$) in the **population** of **patients** to which it's **appropriate** to **generalize** from the **patients** in Your **trial**, and let $D = y = (y_1 \dots y_n)$. where y_i is the **observed difference** ($SBP_{before} - SBP_{after}$) for **patient** i ($i = 1, \dots, n$).

The **real-world purpose** of this **experiment** is to **decide** whether to **take the drug forward to phase III**; under the **weight** of **20th-century**

Decision, Not Inference

inertia (in which **decision-making** was **strongly** — and **incorrectly** — **subordinated** to **inference**), Your **first impulse** might be to **treat this** as an **inferential problem** about θ , but **it's not**; it's a **decision problem** that **involves** θ .

This is an **example** of the

- **Decision-Versus-Inference Principle:** We should all **get out of the habit** of **using inferential methods** to **make decisions**: their **implicit utility structure** is often **far from optimal**.

The **action space** here is $\mathcal{A} = (a_1, a_2) =$ (**don't take the drug forward to phase III, do take it forward**), and a **sensible utility function** $U(a_j, \theta)$ should be **continuous** and **monotonically increasing** in θ over a **broad range** of **positive** θ values (the **bigger** the **SBP decline** for **hypertensive patients** who **start** at (say) **160 mmHg**, the **better**, up to a **drop** of about **40 mmHg**, **beyond** which the **drug** starts inducing **fainting spells**).

However, to **facilitate** a **comparison** between **BIC** and **log scores**, here I'll **compare two models** M_1 and M_2 that **dichotomize** the θ range,

Models For Quantifying Improvement

but not at 0: despite a century of textbook claims to the contrary, there's nothing special about $\theta = 0$ in this setting, and in fact You know scientifically that θ is not exactly 0 (because the outcome variable in this experiment is conceptually continuous).

What matters here is whether $\theta > \Delta$, where Δ is a practical significance improvement threshold below which the drug is not worth advancing into phase III (for example, any drug that did not lower SBP for severely hypertensive patients — those whose pre-drug values average 160 mmHg or more — by at least 15 mmHg would not deserve further attention).

With little information about θ external to this experimental data set, what counts in this situation is the comparison of the following two models:

$$M_1: \left\{ \begin{array}{l} (\theta|\mathcal{B}) \sim \text{diffuse for } \theta \leq \Delta \\ (y_i|\theta\mathcal{B}) \stackrel{\text{iid}}{\sim} N(\theta, \sigma^2) \end{array} \right\} \text{ and} \quad (23)$$

$$M_2: \left\{ \begin{array}{l} (\theta|\mathcal{B}) \sim \text{diffuse for } \theta > \Delta \\ (y_i|\theta\mathcal{B}) \stackrel{\text{iid}}{\sim} N(\theta, \sigma^2) \end{array} \right\}, \quad (24)$$

Quantifying Improvement: Model Comparison Methods

in which **for simplicity** I'll take σ^2 to be **known** (the **results** are **similar** with σ^2 **learned** from the **data**).

This gives rise to **three model-selection methods** that can be **compared calibratively**:

- **Full-sample log scores**: choose M_2 if $LS_{FS}(M_2|y \mathcal{B}) > LS_{FS}(M_1|y \mathcal{B})$.

- **Posterior probability**: let


$M^* = \{(\theta|\mathcal{B}) \sim \text{diffuse on } \mathfrak{R}, (y_i|\theta \mathcal{B}) \stackrel{\text{iid}}{\sim} N(\theta, \sigma^2)\}$ and **choose** M_2 if $p(\theta > \Delta|y M^* \mathcal{B}) > 0.5$.

- **BIC**: choose M_2 if $BIC(M_2|y \mathcal{B}) < BIC(M_1|y \mathcal{B})$.

Simulation experiment details, based on the **SBP drug trial**: $\Delta = 15$;
 $\sigma = 10$; $n = 10, 20, \dots, 100$; **data-generating** $\theta_{DG} = 11, 12, \dots, 19$;
 $\alpha = 0.05$; **1,000 simulation replications**; **Monte-Carlo approximations**
of the **predictive ordinates** in LS_{FS} based on **10,000 posterior draws**.

The **figures** below give **Monte-Carlo estimates** of the **probability that M_2 is chosen**.


LS_{FS} Results: Quantifying Improvement



This exhibits all the **monotonicities** that it **should**, and **correctly yields 0.5** for all n with $\theta_{DG} = 15$.


Posterior Probability Results: Quantifying Improvement

Posterior Probability



Even though the LS_{FS} and **posterior-probability methods** are **quite different**, their **information-processing** in **discriminating** between M_1 and M_2 is **identical** to within ± 0.003 (well within simulation noise with **1,000 replications**).

BIC Results: Quantifying Improvement



Here **BIC** and the **posterior-probability approach** are **algebraically identical**, making the **model-discrimination performance** of **all three approaches** the **same** in **this problem**.

Establishing Bio-Equivalence

- **(establishing bio-equivalence)** In this case there's a **previous hypertension drug B** (call the **new drug A**) and You're wondering if the **mean effects** of the **two drugs** are **close enough** to regard them as **bio-equivalent**.

A **good design** here would again have a **repeated-measures** character, in which **each patient's SBP** is measured **four times**: **before** and **after** taking drug A , and **before** and **after** taking drug B (allowing **enough time** to elapse between **taking the two drugs** for the **effects** of the **first drug** to **disappear**).

Let θ stand for the **mean difference**

$$[(SBP_{before,A} - SBP_{after,A}) - (SBP_{before,B} - SBP_{after,B})] \quad (25)$$

in the **population** of **patients** to which it's **appropriate** to **generalize** from the **patients in Your trial**, and let y_i be the **corresponding difference** for patient i ($i = 1, \dots, n$).

Again in this **setting** there's **nothing special** about $\theta = 0$, and as **before** You **know scientifically** that θ is **not exactly 0**;

Bio-Equivalence Modeling

what **matters** here is whether $|\theta| \leq \lambda$, where $\lambda > 0$ is a **practical significance bio-equivalence threshold** (e.g., **5 mmHg**).

Assuming as before a **Gaussian sampling story** and **little information** about θ **external** to this **experimental data set**, what **counts** here is a **comparison** of

$$M_3: \left\{ \begin{array}{l} (\theta|\mathcal{B}) \sim \text{diffuse for } |\theta| \leq \lambda \\ (y_i|\theta \mathcal{B}) \stackrel{\text{iid}}{\sim} N(\theta, \sigma^2) \end{array} \right\} \quad \text{and} \quad (26)$$

$$M_4: \left\{ \begin{array}{l} (\theta|\mathcal{B}) \sim \text{diffuse for } |\theta| > \lambda \\ (y_i|\theta \mathcal{B}) \stackrel{\text{iid}}{\sim} N(\theta, \sigma^2) \end{array} \right\}, \quad (27)$$

in which σ^2 is again taken for **simplicity** to be **known**.

A **natural alternative** to **BIC** and LS_{FS} here is again based on **posterior probabilities**: as before, let

$$M^* = \{(\theta|\mathcal{B}) \sim \text{diffuse on } \mathfrak{R}, (y_i|\theta \mathcal{B}) \stackrel{\text{iid}}{\sim} N(\theta, \sigma^2)\}, \text{ but this time favor } M_4 \text{ over } M_3 \text{ if } p(|\theta| > \lambda | y, M^* \mathcal{B}) > 0.5.$$

As before, a **careful real-world choice** between M_3 and M_4 in **this case** would be **based** on a **utility function** that **quantified** the

Bio-Equivalence Model Comparison

costs and benefits of


{**claiming** the two drugs were **bio-equivalent** when they **were**,
concluding that they were **bio-equivalent** when they **were not**,
deciding that they were **not bio-equivalent** when they **were**,
judging that they were **not bio-equivalent** when they were **not**},

but here I'll again simply **compare** the **calibrative performance** of
 LS_{FS} , **posterior probabilities**, and **BIC**.

Simulation experiment details, based on the **SBP drug trial**: $\lambda = 5$;
 $\sigma = 10$; $n = 10, 20, \dots, 100$; **data-generating**
 $\theta_{DG} = \{-9, -7, -5, -3, -1, 0, 1, 3, 5, 7, 9\}$; $\alpha = 0.05$; **1,000 simulation**
replications, $M = 10,000$ **Monte-Carlo draws** for LS_{FS} .


NB It has **previously been established** that when **making** the
(unrealistic) sharp-null comparison $\theta = 0$ versus $\theta \neq 0$ in the **context**
of $(y_i | \theta) \stackrel{\text{iid}}{\sim} N(\theta, \sigma^2)$, as $n \rightarrow \infty$ LS_{FS} **selects** the $\theta \neq 0$ **model** with
probability $\rightarrow 1$ even when $\theta_{DG} = 0$; this **“inconsistency of log scores**
at the null model” has been **used by some people** as a **reason to**
dismiss log scores as a **model-comparison method**.

LS.FS




In this **more realistic setting**, comparing $|\theta| \leq \lambda$ versus $|\theta| > \lambda$ with $\lambda > 0$, LS_{FS} has the **correct large-sample behavior**, **both** when $|\theta_{DG}| \leq \lambda$ and when $|\theta_{DG}| > \lambda$.

Posterior Probability Results: Bio-Equivalence




The **qualitative behavior** of the LS_{FS} and **posterior-probability methods** is **identical**, although there are some **numerical differences** (**highlighted** later).

BIC Results: Bio-Equivalence



In the **quantifying-improvement** case, the **BIC** and **posterior-probability** methods were **algebraically identical**; here they **nearly coincide** (differences of ± 0.001 with 1,000 simulation repetitions).


LS.FS Versus BIC (n = 10)



If You call **choosing** M_4 : $|\theta| > \lambda$ when $|\theta_{DG}| \leq \lambda$ a **false-positive** error and **choosing** M_3 : $|\theta| \leq \lambda$ when $|\theta_{DG}| > \lambda$ a **false-negative** mistake, with $n = 10$ there's a **trade-off**: LS_{FS} has more **false positives** and BIC has more **false negatives**.

LS_{FS} Versus BIC Results: Bio-Equivalence

LS.FS Versus BIC (n = 50)



By the time You **reach** $n = 50$ in **this problem**, LS_{FS} and BIC are **essentially equivalent**.

For People Who Like to Test Sharp-Null Hypotheses

An **extreme example** of the **false-positive/false-negative differences** between LS_{FS} and **BIC** in **this setting** may be **obtained**, albeit **unwisely**, by **letting** $\lambda \downarrow 0$.

This is **unwise** here (and is **often unwise**) because it **amounts**, in **frequentist language**, to **testing** the **sharp-null hypothesis** $H_0: \theta = 0$ against the **alternative** $H_A: \theta \neq 0$.

It's **necessary** to **distinguish** between **problems** in which there **is or is not** a **structural singleton** in the **(continuous)** set Θ of **possible values** of θ : **settings** where it's **scientifically important** to **distinguish** between $\theta = \theta_0$ and $\theta \neq \theta_0$ — an **example** would be **discriminating** between $\{\text{these two genes are on different chromosomes (the strength } \theta \text{ of their genetic linkage is } \theta_0 = 0)\}$ and $\{\text{these two genes are on the same chromosome } (\theta > 0)\}$.

Sharp-null testing without **structural singletons** is **always unwise** because

(a) **You already know** from **scientific context**, when the **outcome variable** is **continuous**, that H_0 is **false**, and **(relatedly)**

Testing Sharp-Null Hypotheses (continued)

(b) it's **silly** from a **measurement point of view**: with a **(conditionally) IID** $N(\theta, \sigma^2)$ sample of size n , your **measuring instrument** \bar{y} is only **accurate** to **resolution** $\frac{\sigma}{\sqrt{n}} > 0$; **claiming** to be **able to discriminate** between $\theta = 0$ and $\theta \neq 0$ — with **realistic values** of n — is like **someone** with a **scale** that's **only accurate** to the **nearest ounce** telling You that Your **wedding ring** has **1 gram** (0.035 ounce) **less gold in it** than the **jeweler claims** it does.

Nevertheless, **for people who like to test sharp-null hypotheses**, here are some **results**: here I'm **comparing** the **models** ($i = 1, \dots, n$)

$$M_5: \left\{ \begin{array}{l} (\sigma^2 | \mathcal{B}) \sim \text{diffuse on } (0, \text{large}) \\ (y_i | \sigma^2 \mathcal{B}) \stackrel{\text{iid}}{\sim} N(0, \sigma^2) \end{array} \right\} \text{ and} \quad (28)$$

$$M_6: \left\{ \begin{array}{l} (\theta | \sigma^2 \mathcal{B}) \sim \text{diffuse on } (-\text{large}, \text{large}) \times (0, \text{large}) \\ (y_i | \theta \sigma^2 \mathcal{B}) \stackrel{\text{iid}}{\sim} N(\theta, \sigma^2) \end{array} \right\}, \quad (29)$$


In **this case** a **natural Bayesian competitor** to **BIC** and LS_{FS} would be to **construct** the **central** $100(1 - \alpha)\%$ **posterior interval** for θ under M_6 and **choose** M_6 if **this interval doesn't contain 0**.

Testing Sharp-Null Hypotheses (continued)

Simulation experiment details: data-generating $\sigma_{DG} = 10$; $n = 10, 20, \dots, 100$; data-generating $\theta_{DG} = \{0, 1, \dots, 5\}$; **1,000 simulation replications**, $M = 100,000$ Monte-Carlo draws for LS_{FS} ; the **figures** below give **Monte-Carlo estimates** of the **probability that M_6 is chosen**.

As before, let's call **choosing M_6 : $\theta \neq 0$ when $\theta_{DG} = 0$** a **false-positive** error and **choosing M_5 : $\theta = 0$ when $\theta_{DG} \neq 0$** a **false-negative** mistake.


LS_{FS} Results: Sharp-Null Testing



In the **limit** as $\lambda \downarrow 0$, the LS_{FS} **approach** makes **hardly any false-negative errors** but **quite a lot of false-positive mistakes**.

Interval ($\alpha = 0.05$) Results: Sharp-Null Testing


Posterior Interval (alpha = 0.05)



The **behavior** of the **posterior interval approach** is of course **quite different**: it makes **many false-negative errors** because its **rate of false-positive mistakes is fixed at 0.05**.


Interval (α Modified to LS_{FS} Behavior) Results

Posterior Interval (alpha Modified to LS.FS Behavior)



When the **interval method** is **modified** so that α **matches** the LS_{FS} **behavior** at $\theta_{DG} = 0$ (letting α **vary** with n), the **two approaches** have **identical model-discrimination ability**.


BIC Results: Sharp-Null Testing



BIC's behavior is quite different from that of LS_{FS} and fixed- α posterior intervals: its false-positive rate decreases as n grows, but it suffers a high false-negative rate to achieve this goal.

Interval (α Modified to BIC Behavior) Results

Posterior Interval (alpha Modified to BIC Behavior)



When the **interval method** is **modified** so that α **matches** the **BIC behavior** at $\theta_{DG} = 0$ (again letting α **vary** with n), the **two approaches** have **identical model-discrimination ability**.

LS_{FS} Versus BIC: Geometric Versus Poisson

As another **model-comparison example**, suppose You have an **integer-valued** data set $D = y = (y_1 \dots y_n)$ and You wish to **compare**

$M_7 =$ **Geometric**(θ_1) **sampling distribution** with a **Beta**(α_1, β_1) **prior** on θ_1 , and

$M_8 =$ **Poisson**(θ_2) **sampling distribution** with a **Gamma**(α_2, β_2) **prior** on θ_2 .

LS_{FS} and **BIC** both have **closed-form expressions** in this **situation**:

with $s = \sum_{i=1}^n y_i$ and $\hat{\theta}_1 = \frac{\alpha_1 + n}{\alpha_1 + \beta_1 + s + n}$,

$$\begin{aligned} LS_{FS}(M_7|y \mathcal{B}) &= \log \Gamma(\alpha_1 + n + \beta_1 + s) + \log \Gamma(\alpha_1 + n + 1) \\ &\quad - \log \Gamma(\alpha_1 + n) - \log \Gamma(\beta_1 + s) \quad (30) \\ &\quad + \frac{1}{n} \sum_{i=1}^n [\log \Gamma(\beta_1 + s + y_i) \\ &\quad - \log \Gamma(\alpha_1 + n + \beta_1 + s + y_i + 1)], \end{aligned}$$

$$BIC(M_7|y \mathcal{B}) = -2[n \log \hat{\theta}_1 + s \log(1 - \hat{\theta}_1)] + \log n, \quad (31)$$

Geometric Versus Poisson (continued)

$$\begin{aligned}LS_{FS}(M_8|y\mathcal{B}) &= (\alpha_2 + s) \log(\beta_2 + n) - \log \Gamma(\alpha_2 + s) \\ &\quad - (\alpha_2 + s) \log(\beta_2 + n + 1) \quad (32) \\ &\quad + \frac{1}{n} \sum_{i=1}^n [\log \Gamma(\alpha_2 + s + y_i) - y_i \log(\beta_2 + n + 1) \\ &\quad - \log \Gamma(y_i + 1)], \text{ and}\end{aligned}$$

$$BIC(M_8|y\mathcal{B}) = -2[s \log \hat{\theta}_2 - n \hat{\theta}_2 - \sum_{i=1}^n \log(y_i!)] + \log n, \quad (33)$$

$$\text{where } \hat{\theta}_2 = \frac{\alpha_2 + s}{\beta_2 + n}.$$

Simulation details: $n = \{10, 20, 40, 80\}$, $\alpha_1 = \beta_1 = \alpha_2 = \beta_2 = 0.01$, **1,000 simulation replications**; it **turns out** that with $(\theta_1)_{DG} = 0.5$ (Geometric) and $(\theta_2)_{DG} = 1.0$ (Poisson), **both data-generating distributions are monotonically decreasing and not easy to tell apart by eye.**

Let's call **choosing** M_8 (Poisson) when $M_{DG} = \mathbf{Geometric}$ a **false-Poisson** error and **choosing** M_7 (Geometric) when $M_{DG} = \mathbf{Poisson}$ a **false-Geometric** mistake.

Geometric Versus Poisson (continued)

The **table below** records the **Monte-Carlo probability** that the **Poisson model** was chosen.

M.DG = Poisson			M.DG = Geometric		
n	LS.FS	BIC	n	LS.FS	BIC
10	0.8967	0.8661	10	0.4857	0.4341
20	0.9185	0.8906	20	0.3152	0.2671
40	0.9515	0.9363	40	0.1537	0.1314
80	0.9846	0.9813	80	0.0464	0.0407

Both methods make **more false-Poisson errors** than **false-Geometric mistakes**; the **results reveal once again** that **neither BIC nor LS_{FS} uniformly dominates** — each has a **different pattern** of **false-Poisson** and **false-Geometric errors** (LS_{FS} **correctly identifies the Poisson more often** than **BIC** does, but as a result **BIC gets the Geometric right more often** than LS_{FS}).

- **Log scores** are **entirely free** from the **diffuse-prior** problems **bedeviling Bayes factors**:

$$LS_{FS}(M_j|y \mathcal{B}) = \frac{1}{n} \sum_{i=1}^n \log p(y_i|y M_j \mathcal{B}),$$

in which

$$\begin{aligned} p(y_i|y M_j \mathcal{B}) &= \int p(y_i|\gamma_j M_j \mathcal{B}) p(\gamma_j|y M_j \mathcal{B}) d\gamma_j & (34) \\ &= E_{(\gamma_j|y M_j \mathcal{B})} p(y_i|\gamma_j M_j \mathcal{B}); \end{aligned}$$

this **expectation** is over the **posterior (not the prior) distribution** for the **parameter vector** γ_j in **model** M_j , and is therefore **completely stable** with respect to **small variations** in how **prior diffuseness** (if **scientifically called for**) is **specified**, even with only **moderate** n .

- Following the **Modeling-As-Decision Principle**, the **decision-theoretic justification** for **Bayes factors** involves **not only the Bayes factors themselves** but also the **prior model probabilities**, which can be **hard to specify** in a **scientifically-meaningful way**: under the **Bayes-factor (possibly unrealistic) 0/1 utility structure**,

Properties of LS_{FS} (continued)

You're supposed to **choose the model** with the **highest posterior probability**, not the one with the **biggest Bayes factor**.

By contrast, **specification of prior model probabilities** doesn't arise with **log scores**, which have a **direct decision-theoretic justification** based on the **Prediction Principle**.

- It may **seem** that **log scores** have no **penalty** for **unnecessary model complexity**, but this is **not true**: for example, if **one of Your models** carries around a lot of **unnecessary parameters**, this will **needlessly inflate** its **predictive variances**, making the **heights** of its **predictive densities go down**, thereby **lowering its log score**.
- It may **also seem** that the **behavioral rule** based on **posterior Bayes factors** (Aitkin 1991) is the same as the **rule** based on

LS_{FS} , which **favors model M_j over $M_{j'}$** if

$$n LS_{FS}(M_j|y, \mathcal{B}) > n LS_{FS}(M_{j'}|y, \mathcal{B}). \quad (35)$$

But this is **not true either**: for example, in the **common situation** in which the **data set D** consists of **observations y_i** that are **conditionally IID** from $p(y_i|\eta_j, M_j, \mathcal{B})$ under M_j ,

$$nLS_{FS}(M_j|y, \mathcal{B}) = \log \prod_{i=1}^n \left[\int p(y_i|\eta_j, M_j, \mathcal{B}) p(\eta_j|y, M_j, \mathcal{B}) d\eta_j \right], \quad (36)$$

and this is **not the same as**

$$\log \int \left[\prod_{i=1}^n p(y_i|\eta_j, M_j, \mathcal{B}) \right] p(\eta_j|y, M_j, \mathcal{B}) d\eta_j = \bar{L}_j^{PBF} \quad (37)$$

because the **product** and **integral operators do not commute**.

- Some **take-away messages:**

— In the **bio-equivalence** example, even when You (**unwisely**) let $\lambda \downarrow 0$, thereby **testing a sharp-null hypothesis**, the **asymptotic behavior of log scores is irrelevant**; what **counts** is the **behavior of log scores and Bayes factors** with **Your sample size** and the **models being compared**, and for any given n it's **not possible to say** that the **false-positive/false-negative trade-off** built into **Bayes factors** is **universally better for all applied problems** than the **false-positive/false-negative trade-off** built into **log scores**,

Summary (continued)

or **vice versa** — You have to **think it through** in each problem.

For instance, the **tendency of log scores to choose the “bigger” model in a nested-model comparison is exactly the right qualitative behavior** in the following **two examples** (and **many more such examples exist**):

— **Variable selection in searching through many compounds or genes to find successful treatments**: here a **false-positive mistake** (taking an **ineffective compound or gene forward to the next level of investigation**) costs the **drug company** $\$C$, but a **false-negative error** (**failing to move forward with a successful treatment**, in a **highly-competitive market**) costs $\$k C$ with $k = 10\text{--}100$.

— In a **two-arm clinical-trial** setting, consider the **random-effects Poisson regression model**

$$\begin{aligned} (y_i | \lambda_i, \mathcal{B}) &\stackrel{\text{indep}}{\sim} \text{Poisson}(\lambda_i) \\ \log \lambda_i &= \beta_0 + \beta_1 x_i + e_i \\ (e_j | \sigma_e^2, \mathcal{B}) &\stackrel{\text{iID}}{\sim} N(0, \sigma_e^2), \quad (\beta_0, \beta_1, \sigma_e^2) \sim \text{diffuse}, \end{aligned} \tag{38}$$

Summary (continued)

where the y_i are **counts** of a **relatively rare event** and x_i is **1** for the **treatment group** and **0** for **control**; You would consider **fitting this model** instead of its **fixed-effects counterpart**, obtained by **setting $\sigma_e^2 = 0$** , to **describe unexplainable heterogeneity (Poisson over-dispersion)**.

In this **setting**, **Bayes factors** will make the **mistake** of **{telling You that $\sigma_e^2 = 0$ when it's not}** **more often** than **log scores**, and **log scores** will make the **error** of **{telling You that $\sigma_e^2 > 0$ when it's actually 0}** **more often** than **Bayes factors**, but the **former mistake** is **much worse** than the **latter**, because You will **underpropagate uncertainty** about the **fixed effect β_1** , which is the **whole point of the investigation**.

- **All through this discussion it's vital to keep in mind that**

the **gold standard** for **false-positive/false-negative behavior** is provided **neither by Bayes factors nor by log scores** but instead by **Bayesian decision theory in Your problem**.

Summary (continued)

- **Asymptotic conclusions are often misleading**: while it's **true** that

Old Theorem: $P_{\theta_{DG}=0}(LS_{FS} \text{ chooses } \theta = 0) \rightarrow 0 \text{ as } n \rightarrow \infty,$

it's **also true** that

New Theorem (Draper, 2011): for any $\lambda > 0,$
 $P_{|\theta_{DG}| \leq \lambda}(LS_{FS} \text{ chooses } |\theta| \leq \lambda) \rightarrow 1 \text{ as } n \rightarrow \infty,$

and the **second theorem** would seem to **call the relevance of the first theorem into question**.

- As a **profession**, we need to **strengthen** the progression

Principles \rightarrow **Axioms** \rightarrow **Theorems**

in **optimal model specification**; the **Calibration Principle**, the **Modeling-As-Decision Principle**, the **Prediction Principle** and the **Decision-Versus-Inference Principle** seem **helpful** in **moving toward this goal**.

Is M_1 Good Enough?

What about Q_2 : **Is M_1 good enough?**

As **discussed previously**, by the **Modeling-As-Decision Principle** a **full judgment of adequacy** requires **real-world input** (“To what **purpose** will the model be put?”), so it’s **not possible** to propose **generic methodology** to answer Q_2 (apart from **maximizing expected utility**, with a **utility function** that’s **appropriately tailored** to the **problem at hand**), but the **somewhat related question**

$Q_{2'}$: **Could the data have arisen from model M_j ?**

can be **answered in a general way** by **simulating** from M_j **many times**, developing a **distribution** of (e.g.) LS_{FS} values, and seeing how **unusual** the **actual data set’s log score** is in **this distribution**.

This is **related** to the **posterior predictive model-checking** method of Gelman et al. (1996), which **produces** a P -value.

However, **this sort of thing** needs to be **done carefully** (Draper 1996), or the result will be **poor calibration**; indeed, Bayarri and Berger (2000) and Robins et al. (2000) have **demonstrated** that the

Is M_1 Good Enough? (continued)

Gelman et al. procedure may be **(sharply) conservative**: You may get $P = 0.4$ from Gelman et al. (indicating that **Your model is fine**) when a **well-calibrated** version of **their idea** would have $P = 0.04$ (indicating that it's **not fine**).

Using a **modification** of an **idea** suggested by Robins et al., Draper and Krnjajić (2010) have **developed a simulation-based method** for **accurately calibrating** the **log-score scale** (I'd be happy to **send You the paper**).

How should You **judge how unusual** the **actual data set's log score** is in the **simulation distribution**?

In all of **Bayesian inference, prediction and decision-making**, except for **calibration concerns**, there's **no need** for P -values, but — since this is a **calibrative question** — it's **no surprise** that **tail areas** (or **something else equally ad-hoc**, such as the **ratio** of the **attained height** to the **maximum height** of the **simulation distribution**) arise.

I don't see how to **avoid this ad-hockery** except by **directly answering Q_2 with decision theory** (instead of **answering Q_2' with a tail area**).

- I've offered an **axiomatization** of **inferential, predictive** and **decision-theoretic statistics** based on **information, not belief**, and RT Cox's (1946) notion of **probability** as a measure of the **weight of evidence** in favor of the **truth** of a **true-false proposition** whose **truth status** is **uncertain** for You.

- **Cox's Theorem** lays out a **progression** from

Principles → **Axioms** → **Theorem**

to **prove** that **Bayesian reasoning** is **justified** under natural **logical consistency** assumptions; for me this **secures the foundations of applied probability**.

- But **Cox's Theorem does not go far enough** for **statistical work** in **science**, in **two ways** related to **model specification**:

— **Nothing** in its **consequences** requires You to **pay attention to how often You get the right answer**, which is a **basic scientific concern**, and

Summary (continued)

— it **doesn't offer any advice** on how to **specify the required ingredients**: with θ as the **unknown** of principal interest, \mathcal{B} as **Your relevant background assumptions and judgments**, and an **information source (data set) D** relevant to **decreasing Your uncertainty** about θ , the ingredients are

* $\{p(\theta|\mathcal{B}), p(D|\theta \mathcal{B})\}$ for **inference** and **prediction**, and

* in addition $\{\mathcal{A}, U(a, \theta)\}$ for **decision**, where \mathcal{A} is **Your set of available actions** and $U(a, \theta)$ is **Your utility function** (mapping from **actions a** and unknown θ to **real-valued consequences**).

- To **secure the foundations of statistics**, work is needed laying out the **logical progression**

Principles \rightarrow **Axioms** \rightarrow **Theorems**

for **model specification**; **progress** in this area is **part** of the **Theory of Applied Statistics**.

- A **Calibration Principle** helps address the **first** of the **two deficiencies** above:

Summary (continued)

Calibration Principle: In **model specification**, You should pay attention to **how often You get the right answer**, by creating situations in which **You know what the right answer is** and seeing **how often Your methods recover known truth**.

Interest in **calibration** can be seen to be **natural** in **Bayesian work** by thinking **decision-theoretically**, with a **utility function** that **rewards** both **quality of scientific conclusions** and **good calibration** of the **modeling process yielding those conclusions**.

- In problems of **realistic complexity** You'll generally notice that (a) You're **uncertain** about θ but (b) You're also **uncertain** about how to **quantify Your uncertainty about θ** , i.e., You have **model uncertainty**.

- This **acknowledgment** of Your **model uncertainty** implies a willingness by You to **consider two or more models** in an **ensemble** $\mathcal{M} = \{M_1, M_2, \dots\}$, which gives rise immediately to **two questions**:

Q_1 : Is M_1 **better** than M_2 ? Q_2 : Is M_1 **good enough**?

Summary (continued)

- These questions **sound fundamental** but **are not**: better **for what purpose?** Good enough **for what purpose?** To address the **second** of the **two deficiencies** above (**lack of guidance** from **Cox's Theorem** on **model specification**), this **implies** a

Modeling-As-Decision Principle: Making clear the **purpose to which the modeling will be put** transforms **model specification** into a **decision problem**, solvable by **maximizing expected utility** with a **utility function tailored** to the **specific problem** under study.

This **solves the model-specification problem** but is **hard work**; there's a **powerful desire** for **generic model-comparison methods** whose **utility structure** may provide a **decent approximation** to **problem-specific utility elicitation**.

Two such methods are **Bayes factors** (whose **utility justification** is **less than compelling**) and **log scores**, which are based on the

Prediction Principle: **Good models** make **good predictions**, and **bad models** make **bad predictions**; that's one **scientifically important** way
You know a **model** is **good** or **bad**.

Summary (continued)

- I'm aware of **three approaches** to improved **assessment** and **propagation** of **model uncertainty**: **Bayesian model averaging** (BMA), **Bayesian nonparametric** (BNP) modeling, and **calibration (3-fold) cross-validation** (CCV).
- **CCV** provides a way to **pay the right price** for **hunting around in the data** for **good models**, motivating the following **modeling algorithm**:

- (a) Start at a model M_0 (how choose?); set the current model $M_{\text{current}} \leftarrow M_0$ and the current model ensemble $\mathcal{M}_{\text{current}} \leftarrow \{M_0\}$.
- (b) If M_{current} is good enough to stop (how decide?), return $\mathcal{M}_{\text{current}}$; else
- (c) Generate a new candidate model M_{new} (how choose?) and set $\mathcal{M}_{\text{current}} \leftarrow \mathcal{M}_{\text{current}} \cup M_{\text{new}}$.
- (d) If M_{new} is better than M_{current} (how decide?), set $M_{\text{current}} \leftarrow M_{\text{new}}$.
- (e) Go to (b).

- For the **choice** in (a), there's usually a **default off-the-shelf initial model** based on the **structure** of the **data set** D and the **scientific context**.

Summary (continued)

- In **manual model search** the **choice** in (c) is typically based on the **results** of a variety of **diagnostics**, with the **new model** suggested by **deficiencies** revealed in this way; at present, we have **no better way** to **automate this choice** in many cases than **choosing M_{new} at random** (I offer **no new ideas** on this topic **today**).
- In **comparing M_1 with M_2** (the **choice** in (d)), consider a **calibrative scenario** in which the **data-generating model M_{DG}** is **one** or the **other** of $\mathcal{M} = \{M_1, M_2\}$ (apart from **parameter estimation**), and call $\{\text{choosing } M_2 \text{ when } M_{DG} = M_1\}$ a **false positive** and $\{\text{choosing } M_1 \text{ when } M_{DG} = M_2\}$ a **false negative**; then
 - The **right way** to do this, following the **Modeling-As-Decision Principle**, is to build a **utility function** by **quantifying** the **real-world consequences** of $\{\text{choosing } M_1 \text{ when } M_{DG} = M_1, \text{ choosing } M_1 \text{ when } M_{DG} = M_2, \text{ choosing } M_2 \text{ when } M_{DG} = M_1, \text{ choosing } M_2 \text{ when } M_{DG} = M_2\}$ and **maximize expected utility**.

Summary (continued)

— If instead You **contemplate** using **Bayes factors/BIC** or **log scores**, it is **not the case** that **one** of these two methods **uniformly dominates the other** in **calibrative performance**; in **some settings** they behave the **same**, in others (**for Your sample size**) they will have a **different balance of false positives and false negatives**; it's a good idea to **investigate this** before **settling on one method or the other**.

- See Draper and Krnjajić (2010) for a **method** for **answering the question** Q_2' : **Could the data have arisen from model M_j ?** in a **well-calibrated way**.
- **CCV** provides an **approach** to finding a **good ensemble \mathcal{M} of models**, and gives You a **decent opportunity** both to **arrive at good answers** to **Your main scientific questions** and to **evaluate the calibration** of the **iterative modeling process** that **led You to Your answers**.
- **Decision-Versus-Inference Principle:** We should all **get out of the habit** of **using inferential methods** to **make decisions**: their **implicit utility structure** is often **far from optimal**.

Another Unsolved Foundational Problem

- One more **unsolved foundational problem**: how can **good decisions** be arrived at when “**You**” is a **collective of individuals**, all with **their own utility functions** that imply **partial cooperation** and **partial competition**?

Example: Allocation of **finite resources** by **two or more people** who have **agreed to band together** in some sense (i.e., **politics**, at the level of **family** or **nation** or ...).

An instance of this: **Defining and funding good quality of health care** — the **actors** in the drama include

{**patient, doctor, hospital, state and local regulatory bodies, federal regulatory system**};

all are in **partial agreement** and **partial disagreement** on how (and how many) **resources** should be **allocated** to the **problem** of addressing **this patient's immediate health needs**.

(But that's for **another day**, as is the topic of **Bayesian computing** with **large data sets**.)